ArticleScientific reports2026
Erianin suppresses lung adenocarcinoma by modulating miR-494-3p/MAPK/ERK pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacological activity, molecular mechanisms and therapeutic potential of erianin (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erianin, a compound naturally occurring in Dendrobium, demonstrates a wide spectrum of biological activities, including antitumor properties as well as immunomodulatory actions. Existing studies have found that erianin has inhibitory effects on a variety of cancer cells, including lung cancer. However, the specific mechanism of action of erianin on lung adenocarcinoma (LUAD) has not been fully revealed. This research endeavors to provide preliminary insights into the suppressive effects of eriolin on the progression of LUAD, with a focus on its antitumor mechanisms. The proliferation of LUAD cells in response to erianin was assessed utilizing Cell Counting Kit-8 (CCK-8), wound closure analysis, and colony-forming assays. The impact of erianin on cellular invasion and migration was assessed utilizing the transwell assay methodology. Tube formation assay was used to evaluate the effect of erianin on tumor angiogenesis. The effect of erianin on cell cycle and apoptosis of LUAD cells was determined by flow cytometry. RT-qPCR was used to detect the expression of miR-494-3p in LUAD cells after erianin treatment. In addition, western blotting was used to detect the effect of erianin on protein expression in LUAD cells in vivo and in vitro. Erianin demonstrated the ability to suppress the proliferation, angiogenesis, invasion and migration of LUAD cells in vitro, and arrested the S phase of the cell cycle. Erianin can downregulate the expression of miR-494-3p and exert its anti-cancer effect by affecting the MEGF9/MAPK/ERK/CyclinD1/VEGF-A/Survivin axis in LUAD cells. Our study preliminarily revealed that erianin may exert anti-tumor effects by downregulating the expression of miR-494-3p, thereby regulating the MEGF9/MAPK/ERK/CyclinD1/VEGF-A/Survivin cascade reaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.